
Xiang Ren,1 Peng Wu,1 Liping Wang,1 Mengjie Geng, Lingjia Zeng, Jun Zhang, Ningshao Xia, Shengjie Lai, Harry R. Dalton, Benjamin J. Cowling,2 Hongjie Yu2

We compared the epidemiology of hepatitis A and hepatitis E cases in China from 1990–2014 to better inform policy and prevention efforts. The incidence of hepatitis A cases declined dramatically, while hepatitis E incidence increased. During 2004–2014, hepatitis E mortality rates surpassed those of hepatitis A.

Hepatitis A virus (HAV) and hepatitis E virus (HEV) cause acute hepatitis in humans and are transmitted mainly through the fecal–oral route. Hepatitis A and hepatitis E became notifiable in China in 1990 and 1996, respectively. Since the introduction of the hepatitis A vaccine and the start of mass vaccination in several countries in the 1980s, hepatitis A incidence declined substantially, not only among vaccinated children but in the population as a whole (1,2). China first licensed its live attenuated hepatitis A vaccine in 1992 and later the inactivated hepatitis A vaccine in 2002 (3). The hepatitis A vaccine was initially introduced into the private market, although some provinces provided subsidies through the World Health Organization Expanded Programme on Immunization (http://www.wpro.who.int/china/areas/immunization/en/). Starting in May 2008, hepatitis A vaccinations were incorporated into the routine national childhood immunization program for children >18 months of age (3).

Author affiliations: Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, China (X. Ren, L. Wang, M. Geng, L. Zeng, S. Lai, H. Yu); World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China (X. Ren, P. Wu, B. Cowling); State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University School of Public Health, Xiamen, China (J. Zhang, N. Xia); University of Southampton, Southampton, UK (S. Lai); Royal Cornwall Hospital and European Centre for Environment and Human Health, University of Exeter, Truro, UK (H.R. Dalton); Fudan University School of Public Health, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China (H. Yu)

DOI: http://dx.doi.org/10.3201/eid2302.161095

HEV is a substantial cause of illness and death worldwide, particularly among pregnant women (4). Until the introduction of the first hepatitis E vaccine to private markets in China in 2011, there were no specific pharmaceutical interventions for HEV (5). Given the similarity in diseases caused by HAV and HEV and the recent decline in hepatitis A incidence, we compared the epidemiology of human cases infected with the 2 pathogens in China.

The Study

We obtained data on cases of hepatitis A reported during 1990–2014 and hepatitis E for 1997–2014 from China’s National Notifiable Disease Report System and collated demographic information from the China National Bureau of Statistics. We defined confirmed cases on the basis of dates of disease onset and updated diagnostic criteria issued by the Chinese Ministry of Health in 2008; these criteria are based on epidemiologic history, clinical signs, and laboratory test results (online Technical Appendix Table, https://wwwnc.cdc.gov/EID/article/23/2/16-1095-Techapp1.pdf).

We used R version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria) and SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) to estimate annual incidence and mortality rates for hepatitis A and hepatitis E according to patient age and sex. Notified cases were geocoded into provinces and mapped by ArcGIS 10 (Esri Inc., Redlands, CA, USA). To examine seasonality, we created heat maps by using monthly incidence normalized to the maximum incidence each year. We used a similar approach to examine seasonality across latitudes. We assessed potential associations between incidence and demographic and economic factors by using Poisson regression.

Hepatitis A incidence dropped from 55.7 cases/100,000 person-years in 1991 to 1.9 cases/100,000 person-years in 2014, a decrease of 96.6% (Figure 1). In contrast, hepatitis E incidence increased significantly over this period, from 0.21 cases/100,000 person-years in 1997 to 1.99 cases/100,000 person-years in 2014, an 8-fold increase (p<0.0001 by Poisson regression) (Figure 1). The mortality and incidence rates for hepatitis E overtook those for hepatitis A in 2004 and 2011, respectively (Figure 1). Hepatitis E cases across the country were most frequently reported in March (online Technical Appendix Figures 4, 5). This change may result from increased temperature and rainfall in the spring, which could increase the likelihood of acquiring
HEV infection from exposure to contaminated water, such as water sourced from a stream near a free-range pig farm (6–8). In contrast, the seasonal pattern of HAV infections varied by latitude; cases were reported most frequently in the spring in southern provinces and in the autumn in most northern provinces (online Technical Appendix Figure 5). The decline in the incidence of hepatitis A cases in winter and summer varies by province, and reasons for the differential latitudinal pattern are unclear (7–9).

Hepatitis A incidence was highest among children and young adults (Figure 2). In contrast, hepatitis E incidence was highest among older adults and low among children and young adults (Figure 2). For both diseases, incidence and mortality rates were higher among male patients, and mortality rates tended to increase with age (Figure 2). The percentage of infections resulting in death were generally similar among men and women within each age group for most years (online Technical Appendix Figure 2).

We found considerable changes in the epidemiology of hepatitis A and E over time in mainland China. The major decline in hepatitis A incidence during 1992–2014 cannot be explained solely by the introduction of the vaccine because implementation of vaccinations in the general population had been relatively low until the inactivated hepatitis A vaccine was included in the national Expanded Program on Immunization in May 2008 (3). Other key reasons could be heightened public awareness, improved social hygiene, and upgrades in sewage treatment and water quality (9–11). Decreasing incidence was also accompanied by a change in the age distribution of reported hepatitis A case-patients; the average age increased over time (Figure 2), possibly a consequence of inclusion of the vaccine in the national Expanded Program on Immunization, which targets children >18 months of age. The incidence of hepatitis A is now highest in northwestern China, which is a comparatively less developed region of the country (online Technical Appendix Figure 1).

Our findings in China are similar to those documented in other countries, where HEV infection is now more common than HAV infection (12,13). The increase in hepatitis E incidence could result from either a true increase in the number of cases or from improved case diagnosis. Hepatitis E case-patients are mostly adults, particularly older adults (Figure 2). Although we did not have data on HEV genotypes for this study, it is possible that the change in age distribution of hepatitis E patients may result from the shift of the prevalent HEV genotype in China from genotype 1 to genotype 4 (and, to a lesser extent, genotype 3). Genotype 3 and genotype 4 are known to infect older men (14,15). The increase in the number of HEV infections in eastern China (online Technical Appendix Figure 1) could also be caused by this genotype shift and improved surveillance in these more developed provinces (15), rather than by true geographic heterogeneity in risk factors.

There are some limitations to our study (online Technical Appendix). Our findings are inferred from case notification data, and the data quality could vary because of changes in case definitions. Other limitations include...
variable availability of laboratory diagnostics and lack of hepatitis E genotype data.

Conclusions
Reports of hepatitis A in China have declined substantially, while reports of hepatitis E cases have continued to rise. The mortality rate for hepatitis E surpassed that for hepatitis A in 2004. Decreasing trends of hepatitis A incidence after implementation of a vaccination program targeting children >18 months of age indicate a similar strategy for hepatitis E could be considered as a means to curtail incidence. In addition, variations in demographic, geographic and seasonal distributions of hepatitis A and E may inform future prevention strategies in China.

Acknowledgments
We thank the staff members at the hospitals, local health departments, and county-, district-, prefecture-, and provincial-level centers for disease control and prevention for their valuable assistance in coordinating data collection.
B.J.C. received research funding from Sanofi Pasteur and MedImmune Inc. for studies on influenza vaccination effectiveness. This study was funded by grants from the National Science Fund for Distinguished Young Scholars (no. 81525023), Chinese Center for Disease Control and Prevention’s Key Laboratory of Surveillance and Early-warning on Infectious Disease, the Harvard Center for Communicable Disease Dynamics from the National Institute of General Medical Sciences (grant no. U54 GM088558), and a commissioned grant from the Health and Medical Research Fund from the Government of the Hong Kong Special Administrative Region. The funding bodies had no role in study design, data collection and analysis, preparation of the manuscript, or the decision to publish.

Dr. Ren is an epidemiologist in the Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, and is also a PhD candidate majoring in infectious disease epidemiology at the School of Public Health, the University of Hong Kong.

References


Address for correspondence: Hongjie Yu, School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China; email: cfetpyhj@vip.sina.com

Technical Appendix

Regional Hepatitis Incidence

Provinces along the Yangtze River and some northeastern provinces had relatively higher hepatitis A incidence in the 1990s, while a higher incidence has been observed in western China since 2000 (Technical Appendix Figure 1). In contrast, hepatitis E incidence has remained highest in eastern China (Technical Appendix Figure 1). In the Poisson regression models, both GDP and GDP per capita (Technical Appendix Figure 3) showed a strong association with the incidence of hepatitis A (p < 0.0001) and the incidence of hepatitis E (p < 0.0001). GDP and GDP per capita were inversely correlated with incidence of hepatitis A but positively associated with the incidence of hepatitis E.

Study Limitations

There are some potential limitations to our work. First, the data quality may be influenced by changes in the national notifiable disease reporting system including changes in case definitions, reporting methods, availability of health facilities and laboratory diagnostics, under reporting, and completeness and accuracy of data over the years. Diagnosis and notification of cases may vary across the country, affecting our geographic comparisons of incidence. Second, we inferred the relative disease burden of hepatitis A and E on the basis of case notification data, but underestimation of hepatitis A or E cases may have biased our comparison since many cases may not have been diagnosed and reported. Information on hepatitis E genotypes was not available in the case reports, and therefore we could not explore the potential effect of changing patterns in the genotypes on HEV infections in. In addition, the increase in hepatitis E could be due to increased awareness of the disease and use of diagnostic testing and. We cannot be certain if there has been a true increase in incidence as data on the total number of cases tested for HEV
over the study period are not available. Finally, we did not have information on the total number of laboratory tests performed over time, and increase in laboratory capacity may have led to gradual increases in the incidence of notified cases of hepatitis A and E over time.
## Technical Appendix Table. Change of diagnostic criteria for viral hepatitis A and viral hepatitis E in China*

<table>
<thead>
<tr>
<th>Laboratory Tests</th>
<th>Clinical Description</th>
<th>Epidemiologic Linkage</th>
<th>Diagnostic Criteria and Principles of Management for Viral Hepatitis A</th>
<th>Diagnostic Criteria and Principles of Management for Viral Hepatitis E</th>
<th>Diagnostic Criteria and Principles of Management for Hepatitis E</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1 has abnormal serum alanine aminotransferase (ALT)</td>
<td>2.1 has symptoms of fever, fatigue, loss of appetite, nausea and vomiting in the recent week with exclusion of other diseases, and has hepatomegaly with tenderness or percussion pain</td>
<td>1.1 has epidemiologic history of contact with acute hepatitis A patient or having ingested contaminated food or water in 45 d before onset of illness</td>
<td>GB 17010—1997</td>
<td>WS 298–2008</td>
<td>GB 17011—1997</td>
</tr>
<tr>
<td>3.2 tests positive for the IgM antibody to hepatitis A virus by MAC ELISA or tests IgG antibody to hepatitis A virus 4 times of increasing by competitive inhibition ELISA</td>
<td>2.2 has jaundice with exclusion of other diseases</td>
<td>1.1 has epidemiologic history of contact with a laboratory-confirmed acute hepatitis A patient or has ingested contaminated food or water in 2–7 weeks before onset of illness, or lives in the place with recent hepatitis A epidemic or outbreak, or has history of travel to hepatitis A epidemic area</td>
<td>Chinese Ministry of Health</td>
<td>Chinese Ministry of Health</td>
<td>Chinese Ministry of Health</td>
</tr>
<tr>
<td>3.2 has total serum bilirubin (TBIL) over 1 times larger than the normal upper limits and/or positive urinary bilirubin tests</td>
<td>2.3 has jaundice rapidly deepened</td>
<td>1.1 has epidemiologic history of contact with hepatitis patient or ingested contaminated food or water in 2–6 weeks before onset of illness or has history of travel to high hepatitis E prevalence area or hepatitis E epidemic area</td>
<td>1997/10/6</td>
<td>2008/12/11</td>
<td>2009/6/15</td>
</tr>
<tr>
<td>3.3 has serum bilirubin (BIL) &gt; 17.1 µmol/L (&gt;10 mg/L) or positive</td>
<td>2.4 has mental or neurologic symptoms (Hepatic Encephalopathy) within 10 d after the onset with exclusion of other reasons</td>
<td>1.1 has epidemiologic history of contact with a laboratory-confirmed hepatitis E patient, or ingested contaminated food or water in 15–75 d before onset of illness, or has history of travel to hepatitis E high prevalence area or hepatitis E epidemic area</td>
<td>WS 298, WS 301</td>
<td>WS 301–2008</td>
<td></td>
</tr>
<tr>
<td>3.1 has increasing serum alanine aminotransferase (ALT)</td>
<td>2.5 has jaundice with exclusion of other diseases</td>
<td>1.1 has epidemiologic history of contact with hepatitis patient or ingested contaminated food or water in 2–6 weeks before onset of illness or has history of travel to high hepatitis E prevalence area or hepatitis E epidemic area</td>
<td>Chinese Ministry of Health</td>
<td>Chinese Ministry of Health</td>
<td>Chinese Ministry of Health</td>
</tr>
<tr>
<td>3.3 has serum bilirubin (BIL) &gt; 17.1 µmol/L (&gt;10 mg/L) or positive</td>
<td>2.6 has jaundice with exclusion of other diseases</td>
<td>1.1 has epidemiologic history of contact with hepatitis patient or ingested contaminated food or water in 2–6 weeks before onset of illness or has history of travel to high hepatitis E prevalence area or hepatitis E epidemic area</td>
<td>Chinese Ministry of Health</td>
<td>Chinese Ministry of Health</td>
<td>Chinese Ministry of Health</td>
</tr>
<tr>
<td>3.2 has decreasing serum alanine aminotransferase (ALT)</td>
<td>2.7 has jaundice with exclusion of other diseases</td>
<td>1.1 has epidemiologic history of contact with hepatitis patient or ingested contaminated food or water in 2–6 weeks before onset of illness or has history of travel to high hepatitis E prevalence area or hepatitis E epidemic area</td>
<td>Chinese Ministry of Health</td>
<td>Chinese Ministry of Health</td>
<td>Chinese Ministry of Health</td>
</tr>
</tbody>
</table>

*Diagnostic Criteria of Viral Hepatitis A—1997; Diagnostic Criteria of Viral Hepatitis E—2008; Diagnostic Criteria of Hepatitis E—2009.

**Note:** The data provided is based on the diagnostic criteria outlined in the referenced tables and does not represent the full context or comprehensive coverage of the topic. For further detailed information, please consult the original source or relevant medical literature.
### Standard Name

<table>
<thead>
<tr>
<th>Diagnostic Criteria and Principles of Management for Viral Hepatitis A</th>
<th>Diagnostic Criteria of Viral Hepatitis A</th>
<th>Diagnostic Criteria and Principles of Management for Viral Hepatitis E</th>
<th>Diagnostic Criteria for Hepatitis E</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.3 has serum bilirubin (BIL) &gt; 17.1 µmol/L and positive urinary bilirubin tests</td>
<td>3.3 tests positive for the IgM antibody to hepatitis A virus by ELISA or tests IgG antibody to hepatitis A virus 4 times of increasing by competitive inhibition ELISA or tests hepatitis A RNA positive by RT-PCR</td>
<td>3.3 has total serum bilirubin (TBL) &gt; 17.1 µmol/L (&gt;10mg/L) and/or positive urobilirubin tests</td>
<td>3.3 has serum bilirubin increased over 171 µmol/L</td>
</tr>
<tr>
<td>3.4 has serum bilirubin (BIL) increased, especially the direct bilirubin, with alkaline phosphatase (ALP), glutamin peptidase (GPT) and cholesterol increased, and serum alanine moderately increased</td>
<td>3.4 has serum bilirubin increased, especially the direct bilirubin, with alkaline phosphatase (ALP), glutamin peptidase (GPT) and cholesterol increased, and serum alanine moderately increased</td>
<td>3.4 tests positive for the IgM antibody to hepatitis E virus or tests IgG antibody to hepatitis E virus from negative to positive or titer from low to high or high to low with over quadruple of change by EIA kit</td>
<td>3.4 for patients with liver failure, has prothrombin activity progressively decreased to less than 40%</td>
</tr>
<tr>
<td>3.5 has abnormal liver function, serum bilirubin increased to over 171 µmol/L within a few days or increased by more than 17.1 µmol/L per day, and prothrombin activity less than 40%</td>
<td>3.5 has abnormal liver function, serum bilirubin increased to over 171 µmol/L within a few days or increased by more than 17.1 µmol/L per day, and prothrombin activity less than 40%</td>
<td>3.5 serum bilirubin increased to over 171 µmol/L</td>
<td>3.5 excludes the acute hepatitis A/B/C from serum test</td>
</tr>
<tr>
<td>3.6 has abnormal liver function, transaminase level decreased but the serum bilirubin continued to be elevated, Albumin globulin ratio (A/G) &lt; 1, cholesterol decreased and prothrombin activity less than 40%</td>
<td>3.6 has abnormal liver function, transaminase level decreased but the serum bilirubin continued to be elevated, Albumin globulin ratio (A/G) &lt; 1, cholesterol decreased and prothrombin activity less than 40%</td>
<td>3.7 serum bilirubin increased by 17.1 µmol/L daily</td>
<td>3.7 serum bilirubin increased by 17.1 µmol/L daily</td>
</tr>
</tbody>
</table>

### Diagnosis and Classification

<table>
<thead>
<tr>
<th>Diagnosis and Classification</th>
<th>4.1 Acute anicteric hepatitis</th>
<th>4.2 Acute icteric hepatitis</th>
<th>4.3 Cholestasis hepatitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1 acute anicteric hepatitis</td>
<td>4.1.1 Hepatitis A</td>
<td>4.2.1 Probable case: 2.1+2.3+2.4+3.2</td>
<td>4.3.1 Probable case: 2.1+2.2+2.3+3.4</td>
</tr>
<tr>
<td>4.1.1 Probable case: 1.1+2.1+2.2+3.1</td>
<td>4.1.2 Confirmed case: 4.1.1+3.2</td>
<td>4.2.2 Confirmed case: 2.1+2.2+2.3+3.4+3.5</td>
<td>4.3.2 Confirmed case: 4.3.1+3.2</td>
</tr>
<tr>
<td>4.1.2 Confirmed case: 4.1.1+3.2</td>
<td>4.1.1+2.1+2.2+3.1+3.2</td>
<td>4.2.2 Confirmed case: 4.1.1+3.2+3.3+3.5</td>
<td>4.3.1 Probable case: 2.1+2.2+2.3+3.1+3.2+3.3+3.4</td>
</tr>
<tr>
<td>4.1.1+2.1+2.2+3.1+3.2</td>
<td>4.1.2 Confirmed case: 4.1.1+3.2</td>
<td>4.2.2 Confirmed case: 2.1+2.2+2.3+3.1+3.2+3.3+3.5</td>
<td>4.3.1 Probable case: 2.1+2.2+2.3+3.1+3.2+3.3+3.4</td>
</tr>
<tr>
<td>4.1.2 Confirmed case: 4.1.1+3.2</td>
<td>4.1.1+2.1+2.2+3.1+3.2</td>
<td>4.2.2 Confirmed case: 2.1+2.2+2.3+3.1+3.2+3.3+3.4+3.5</td>
<td>4.3.1 Probable case: 2.1+2.2+2.3+3.1+3.2+3.3+3.4+3.5</td>
</tr>
<tr>
<td>4.1.2 Confirmed case: 4.1.1+3.2</td>
<td>4.1.1+2.1+2.2+3.1+3.2</td>
<td>4.2.2 Confirmed case: 2.1+2.2+2.3+3.1+3.2+3.3+3.4+3.5+3.6</td>
<td>4.3.1 Probable case: 2.1+2.2+2.3+3.1+3.2+3.3+3.4+3.5+3.6</td>
</tr>
<tr>
<td>4.1.2 Confirmed case: 4.1.1+3.2</td>
<td>4.1.1+2.1+2.2+3.1+3.2</td>
<td>4.2.2 Confirmed case: 2.1+2.2+2.3+3.1+3.2+3.3+3.4+3.5+3.6</td>
<td>4.3.1 Probable case: 2.1+2.2+2.3+3.1+3.2+3.3+3.4+3.5+3.6</td>
</tr>
</tbody>
</table>

### Notes

*The revised diagnostic criteria in 2008 provided a simplified disease categorization for hepatitis A and clarified laboratory confirmation for IgG and IgM antibody using ELISA and HAV RNA using RT-PCR. The hepatitis E laboratory testing guidelines were changed in 2008 to include quantification of IgG and IgM antibody using suggested assays.*
Technical Appendix Figure 1. Averaged annual incidence of notifications of hepatitis A (left column) and hepatitis E (right column) in each province of China in 1990–1999, 2000–2009 and 2010–2014. Data were not available on hepatitis A and E cases in Hong Kong SAR, Macau SAR, and Taiwan. Chongqing municipality has been administratively separated from Sichuan province since 1997, and therefore estimates of incidence and mortality rates of hepatitis A in Sichuan province before 1997 were calculated by using data that included Chongqing.
Technical Appendix Figure 2. Point estimates (dots) and 95% confidence intervals (vertical gray lines) of the case fatality ratio (defined as notified deaths divided by all notifications) of hepatitis A and E by age group among males (blue) and females (red) in 1990–1999, 2000–2009 and 2010–2014.
Technical Appendix Figure 4. Seasonal patterns in incidence of notified hepatitis A (upper panel) and hepatitis E (lower panel) cases by year in China from 1990 through 2014. The monthly incidence was calculated for each year and then divided by the maximum monthly incidence in each year.
Technical Appendix Figure 5. Seasonal patterns in incidence of notified hepatitis A (upper panel) and hepatitis E (lower panel) cases by province from 1990 through 2014. The monthly incidence was calculated for each province and then divided by the maximum monthly incidence in each province. The provinces are sorted by latitude from north to south.